Orellanine: From Fungal Origin to a Potential Future Cancer Treatment

Fungal metabolites represent an underutilized resource in the development of novel anticancer drugs. This review will focus on the promising fungal nephrotoxin orellanine, found in mushrooms including Cortinarius orellanus (Fools webcap). Emphasis will be placed on its historical significance, structural features, and associated toxicomechanics. Chromatographic methods for analysis of the compound and its metabolites, its synthesis, and chemotherapeutic potential are also discussed. Although orellanine’s exceptional selectivity for proximal tubular cells is well documented, the mechanics of its toxicity in kidney tissue remains disputed. Here, the most commonly proposed hypotheses are detailed in the context of the molecule’s structure, the symptoms seen following ingestion, and its characteristic prolonged latency period. Chromatographic analysis of orellanine and its related substances remains challenging, while biological evaluation of the compound is complicated by uncertainty regarding the role of active metabolites. This has limited efforts to structurally refine the molecule; despite numerous established methods for its synthesis, there is minimal published material on how orellanine’s structure might be optimized for therapeutic use. Despite these obstacles, orellanine has generated promising data in preclinical studies of metastatic clear cell renal cell carcinoma, leading to the early 2022 announcement of phase I/II trials in humans.

[1]  J. Guitton,et al.  Comment on "Determination of Orellanine in Human Biological Matrices Using Liquid Chromatography with High-Resolution Mass Spectrometry Detection: A Validated Method Applied to Suspected Poisoning Cases". , 2023, Journal of analytical toxicology.

[2]  Young-A. Heo Mirvetuximab Soravtansine: First Approval , 2023, Drugs.

[3]  Yu Zhang,et al.  Antibody drug conjugate: the “biological missile” for targeted cancer therapy , 2022, Signal Transduction and Targeted Therapy.

[4]  M. Labadie,et al.  Determination of Orellanine in Human Biological Matrices Using Liquid Chromatography with High-Resolution Mass Spectrometry Detection: A Validated Method Applied to Suspected Poisoning Cases. , 2022, Journal of analytical toxicology.

[5]  M. Pettinato Introduction to Antibody-Drug Conjugates , 2021, Antibodies.

[6]  P. Ferron,et al.  Toxic Effects of Amanitins: Repurposing Toxicities toward New Therapeutics , 2021, Toxins.

[7]  Xinbo Zhou,et al.  Antibody–drug conjugates: Recent advances in linker chemistry , 2021, Acta pharmaceutica Sinica. B.

[8]  Zengjun Wang,et al.  Patterns of distant metastases in patients with clear cell renal cell carcinoma––A population‐based analysis , 2020, Cancer medicine.

[9]  C. Dumontet,et al.  Antibody–Drug Conjugates: The Last Decade , 2020, Pharmaceuticals.

[10]  David J Newman,et al.  Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. , 2020, Journal of natural products.

[11]  A. Tinker,et al.  A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. , 2019, Clinical genitourinary cancer.

[12]  Jin-Ming Gao,et al.  Mushroom Toxins: Chemistry and Toxicology. , 2019, Journal of agricultural and food chemistry.

[13]  B. Rumack,et al.  Mushroom poisoning: A proposed new clinical classification , 2019, Toxicon : official journal of the International Society on Toxinology.

[14]  Deman Najar Advanced renal cell carcinoma - The role of orellanine and associated therapeutic challenges , 2018 .

[15]  C. Lutz,et al.  Amanitins and their development as a payload for antibody-drug conjugates. , 2018, Drug discovery today. Technologies.

[16]  M. Atkins,et al.  Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma. , 2018, Cancer treatment reviews.

[17]  Hanchen Xu,et al.  Drug resistance and new therapies in colorectal cancer , 2018, World journal of gastroenterology.

[18]  C. Sihlbom,et al.  Pharmacokinetic Properties of the Nephrotoxin Orellanine in Rats , 2018, Toxins.

[19]  J. Diaz Amatoxin-Containing Mushroom Poisonings: Species, Toxidromes, Treatments, and Outcomes. , 2018, Wilderness & environmental medicine.

[20]  C. Sihlbom,et al.  Orellanine specifically targets renal clear cell carcinoma , 2017, Oncotarget.

[21]  B. Haraldsson,et al.  Long-term clinical outcome for patients poisoned by the fungal nephrotoxin orellanine , 2017, BMC Nephrology.

[22]  Daniel H. Huson,et al.  Neanderthal behaviour, diet, and disease inferred from ancient DNA in dental calculus , 2017, Nature.

[23]  C. Porta,et al.  Choosing the right cell line for renal cell cancer research , 2016, Molecular Cancer.

[24]  F. Carvalho,et al.  Human and experimental toxicology of orellanine , 2016, Human & experimental toxicology.

[25]  W. Rumbeiha,et al.  Improved Tissue-Based Analytical Test Methods for Orellanine, a Biomarker of Cortinarius Mushroom Intoxication , 2016, Toxins.

[26]  W. Rumbeiha,et al.  A novel orellanine containing mushroom Cortinarius armillatus. , 2016, Toxicon : official journal of the International Society on Toxinology.

[27]  R. Kiss,et al.  Toward a Cancer Drug of Fungal Origin , 2015, Medicinal research reviews.

[28]  M. Kumwenda,et al.  Successful living related kidney transplantation for end-stage renal failure caused by orellanine syndrome. , 2015, QJM : monthly journal of the Association of Physicians.

[29]  Xiongbin Lu,et al.  Abstract A36: TP53 loss creates therapeutic vulnerability in colorectal cancer , 2017 .

[30]  H. Hedman Defining orellanine as treatment of advanced renal cell carcinoma , 2014 .

[31]  I. Brondz Structure Elucidation of a New Toxin from the Mushroom Cortinarius rubellus Using Gas Chromatography-Mass Spectrometry (GC-MS) , 2013 .

[32]  S. Kaul,et al.  Endophytic fungi from medicinal plants: a treasure hunt for bioactive metabolites , 2012, Phytochemistry Reviews.

[33]  Julia Kerschbaum,et al.  High-dose antioxidant therapy and steroids might improve the outcome of acute renal failure from intoxication by Cortinarius rubellus: report of two cases , 2012, Clinical kidney journal.

[34]  K. Hellenäs,et al.  Analysis of the mushroom nephrotoxin orellanine and its glucosides. , 2012, Journal of natural products.

[35]  M. Millward,et al.  Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel , 2012, Investigational New Drugs.

[36]  W. Mason,et al.  Phase II study of PX-866 in recurrent glioblastoma. , 2012, Neuro-oncology.

[37]  Gerhard Moldenhauer,et al.  Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. , 2012, Journal of the National Cancer Institute.

[38]  E. Nevo,et al.  A direct gas chromatography-mass spectrometry (GC-MS) method for the detection of orellanine present in stomach content (Part I) , 2012 .

[39]  I. Brondz,et al.  A High Performance Liquid Chromatography-Mass Spectrometry (HPLC-MS) Qualitative Detection Method Developed for In Vivo Analyses of Toxin Orellanine from the Cortinarius orellanus Fr.—Part II , 2012 .

[40]  M. Kirchmair,et al.  Fatal renal failure caused by Cortinarius mushrooms , 2011, Pediatric Nephrology.

[41]  L. Nieminen,et al.  Sex differences in renal damage induced in the rat by the Finnish mushroom, Cortinarius speciosissimus. , 2009, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

[42]  B. Haraldsson,et al.  The fungal nephrotoxin orellanine simultaneously increases oxidative stress and down-regulates cellular defenses. , 2008, Free radical biology & medicine.

[43]  N. Rowan,et al.  Medicinal Mushrooms and Cancer Therapy: translating a traditional practice into Western medicine , 2006, Perspectives in biology and medicine.

[44]  T. Sitter,et al.  Treatment of intoxication with Cortinarius speciosissimus using an antioxidant therapy. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[45]  M. Spiteller,et al.  Occurrence of the fungal toxin orellanine as a diglucoside and investigation of its biosynthesis. , 2003, Angewandte Chemie.

[46]  K. Høiland,et al.  The presence of orellanine in spores and basidiocarp from Cortinarius orellanus and Cortinarius rubellus , 2002, Mycologia.

[47]  H. Oubrahim,et al.  DNA strand scission by the nephrotoxin [2,2′-bipyridine]-3,3′,4,4′-tetrol-1,1′-dioxide and related compounds in the presence of iron , 2000, Free radical research.

[48]  I. Macphee,et al.  Acute renal failure from intoxication by Cortinarius orellanus: recovery using anti-oxidant therapy and steroids. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[49]  R. Confalonieri,et al.  Lack of Efficacy of Early Plasma Exchange in Renal Toxicity from Cortinarius orellanus , 1999, Nephron.

[50]  X. Lens,et al.  Voluntary Ingestion of Cortinarius Mushrooms Leading to Chronic Interstitial Nephritis , 1998, American Journal of Nephrology.

[51]  W. Hörl,et al.  Magic mushrooms: hope for a ‘cheap high’ resulting in end-stage renal failure , 1996 .

[52]  I. Blohmé,et al.  Renal transplantation after Cortinarius speciosissimus poisoning. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[53]  B. Rumack,et al.  Handbook of Mushroom Poisoning: Diagnosis and Treatment , 1994 .

[54]  C. Ruedl,et al.  Differential inhibitory action of the fungal toxin orellanine on alkaline phosphatase isoenzymes. , 1989, Biochimica et biophysica acta.

[55]  C. Andary,et al.  Chemotaxonomic study of orellanine in species of Cortinarius and Dermocybe , 1988 .

[56]  H. Gerlach,et al.  Synthese von Orellin , 1988 .

[57]  J. Richard,et al.  Electrochemical study of the mushroom toxin orellanine and of related pyridine-1-oxides—I. Reduction , 1988 .

[58]  G. B. Henegouwen,et al.  IRREVERSIBLE BINDING OF CHLORDIAZEPOXIDE TO HUMAN PLASMA PROTEIN INDUCED BY UV‐A RADIATION , 1986, Photochemistry and photobiology.

[59]  J. Ammirati,et al.  Orellanine and Other Fluorescent Compounds in the Genus Cortinarius, Section Orellani , 1985 .

[60]  W. Z. Antkowiak,et al.  Synthesis of 2-(2′-hydroxyphenyl)pyridine-N-oxide and its thermal decomposition as a model reaction of orellanine deoxidation , 1985 .

[61]  J. Chanal,et al.  PHOTOPHARMACOLOGY OF THE TRANQUILIZER CHLORDIAZEPOXIDE IN RELATION TO ITS PHOTOTOXICITY , 1983, Photochemistry and photobiology.

[62]  M. Möttönen,et al.  Damage Caused by Tw o Finnish Mushrooms, Cortinarius speciosissimus and Cortinarius gentilis on the Rat Kidney , 1975, Zeitschrift fur Naturforschung. Section C, Biosciences.

[63]  J. Mustonen,et al.  Nephrology Dialysis Transplantation , 2017 .

[64]  U. Schubert,et al.  Synthesis of 2,2-Bipyridines: Versatile Building Blocks for Sexy Architectures and Functional Nanomaterials , 2004 .

[65]  H. Oubrahim,et al.  Peroxidase-mediated oxidation, a possible pathway for activation of the fungal nephrotoxin orellanine and related compounds. ESR and spin-trapping studies. , 1998, Free radical research.

[66]  J. Richard,et al.  Generation of oxygen radicals from iron complex of orellanine, a mushroom nephrotoxin; preliminary ESR and spin-trapping studies. , 1998, Free radical research.

[67]  M. Kirchmair,et al.  Orellanine poisoning: rapid detection of the fungal toxin in renal biopsy material. , 1997, Journal of toxicology. Clinical toxicology.

[68]  J. Richard,et al.  Chromatographic behaviour and determination of orellanine, a toxin from the mushroom Cortinarius orellanus. , 1989, Journal of chromatography.

[69]  P. Ravanel,et al.  Phytotoxicity of orellanine, a mushroom toxin. , 1987, Toxicon : official journal of the International Society on Toxinology.

[70]  J. Ahlmén,et al.  Isolation and nephrotoxic studies of orellanine from the mushroom Cortinarius speciosissimus. , 1987, Toxicon : official journal of the International Society on Toxinology.

[71]  G. Decker,et al.  Agricultural chemicals. , 1960, Federation proceedings.